Related Experiment Video
Updated: Jun 20, 2026

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels
Ivica Grgic1, Eva Kiss, Brajesh P Kaistha
1Department of Internal Medicine and Nephrology, Philipps-University, 35033 Marburg, Germany.
Abstract:
Proliferation of interstitial fibroblasts is a hallmark of progressive renal fibrosis commonly resulting in chronic kidney failure. The intermediate-conductance Ca(2+)-activated K(+) channel (K(Ca)3.1) has been proposed to promote mitogenesis in several cell types and contribute to disease states characterized by excessive proliferation. Here, we hypothesized that K(Ca)3.1 activity is pivotal for renal fibroblast proliferation and that deficiency or pharmacological blockade of K(Ca)3.1 suppresses development of renal fibrosis. We found that mitogenic stimulation up-regulated K(Ca)3.1 in murine renal fibroblasts via a MEK-dependent mechanism and that selective blockade of K(Ca)3.1 functions potently inhibited fibroblast proliferation by G(0)/G(1) arrest. Renal fibrosis induced by unilateral ureteral obstruction (UUO) in mice was paralleled by a robust up-regulation of K(Ca)3.1 in affected kidneys. Mice lacking K(Ca)3.1 (K(Ca)3.1(-/-)) showed a significant reduction in fibrotic marker expression, chronic tubulointerstitial damage, collagen deposition and alphaSMA(+) cells in kidneys after UUO, whereas functional renal parenchyma was better preserved. Pharmacological treatment with the selective K(Ca)3.1 blocker TRAM-34 similarly attenuated progression of UUO-induced renal fibrosis in wild-type mice and rats. In conclusion, our data demonstrate that K(Ca)3.1 is involved in renal fibroblast proliferation and fibrogenesis and suggest that K(Ca)3.1 may represent a therapeutic target for the treatment of fibrotic kidney disease.
Insights
Blocking the intermediate-conductance Ca(2+)-activated K(+) channel (K(Ca)3.1) inhibits renal fibroblast proliferation and reduces kidney fibrosis. Targeting K(Ca)3.1 offers a potential therapeutic strategy for fibrotic kidney disease.
Area of Science:
- Nephrology
- Cell Biology
- Pharmacology
Background:
- Interstitial fibroblast proliferation drives renal fibrosis and chronic kidney failure.
- The intermediate-conductance Ca(2+)-activated K(+) channel (K(Ca)3.1) is implicated in mitogenesis and proliferative diseases.
Purpose of the Study:
- To investigate the role of K(Ca)3.1 in renal fibroblast proliferation and the development of kidney fibrosis.
- To determine if K(Ca)3.1 deficiency or blockade can suppress renal fibrosis.
Main Methods:
- Assessed K(Ca)3.1 expression and function in murine renal fibroblasts under mitogenic stimulation.
- Utilized unilateral ureteral obstruction (UUO) model in K(Ca)3.1 knockout and wild-type mice, and treated wild-type mice and rats with a K(Ca)3.1 blocker (TRAM-34).
- Evaluated fibrotic markers, tubulointerstitial damage, collagen deposition, and alphaSMA expression in kidneys.
Main Results:
- Mitogenic stimulation upregulated K(Ca)3.1 in renal fibroblasts via a MEK-dependent pathway.
- Selective K(Ca)3.1 blockade inhibited fibroblast proliferation by inducing G(0)/G(1) arrest.
- K(Ca)3.1 knockout mice exhibited reduced renal fibrosis markers and damage post-UUO.
- Pharmacological inhibition of K(Ca)3.1 attenuated UUO-induced renal fibrosis in mice and rats.
Conclusions:
- K(Ca)3.1 plays a crucial role in renal fibroblast proliferation and fibrogenesis.
- K(Ca)3.1 represents a promising therapeutic target for treating fibrotic kidney diseases.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Potassium-Sparing Diuretics
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Direct Renin Inhibitors